PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells

PLoS One. 2013;8(1):e50128. doi: 10.1371/journal.pone.0050128. Epub 2013 Jan 23.

Abstract

Background: It has been reported that peroxisome proliferator-activated receptor (PPAR)-γ and their synthetic ligands have direct effects on pancreatic β-cells. We investigated whether PPAR-γ activation stimulates insulin secretion through the up-regulation of GPR40 in pancreatic β-cells.

Methods: Rat insulinoma INS-1 cells and primary rat islets were treated with rosiglitazone (RGZ) and/or adenoviral PPAR-γ overexpression. OLETF rats were treated with RGZ.

Results: PPAR-γ activation with RGZ and/or adenoviral PPAR-γ overexpression increased free fatty acid (FFA) receptor GPR40 expression, and increased insulin secretion and intracellular calcium mobilization, and was blocked by the PLC inhibitors, GPR40 RNA interference, and GLUT2 RNA interference. As a downstream signaling pathway of intracellular calcium mobilization, the phosphorylated levels of CaMKII and CREB, and the downstream IRS-2 and phospho-Akt were significantly increased. Despite of insulin receptor RNA interference, the levels of IRS-2 and phospho-Akt was still maintained with PPAR-γ activation. In addition, the β-cell specific gene expression, including Pdx-1 and FoxA2, increased in a GPR40- and GLUT2-dependent manner. The levels of GPR40, phosphorylated CaMKII and CREB, and β-cell specific genes induced by RGZ were blocked by GW9662, a PPAR-γ antagonist. Finally, PPAR-γ activation up-regulated β-cell gene expressions through FoxO1 nuclear exclusion, independent of the insulin signaling pathway. Based on immunohistochemical staining, the GLUT2, IRS-2, Pdx-1, and GPR40 were more strongly expressed in islets from RGZ-treated OLETF rats compared to control islets.

Conclusion: These observations suggest that PPAR-γ activation with RGZ and/or adenoviral overexpression increased intracellular calcium mobilization, insulin secretion, and β-cell gene expression through GPR40 and GLUT2 gene up-regulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae
  • Animals
  • Calcium / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / genetics
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism
  • Cell Line, Tumor
  • Cyclic AMP Response Element-Binding Protein / genetics
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Fatty Acids, Nonesterified / metabolism
  • Gene Expression Regulation / drug effects
  • Genetic Vectors
  • Glucose Transporter Type 2 / genetics
  • Glucose Transporter Type 2 / metabolism
  • Homeodomain Proteins / genetics
  • Homeodomain Proteins / metabolism
  • Insulin / metabolism*
  • Insulin Receptor Substrate Proteins / genetics
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / metabolism
  • Insulin-Secreting Cells / pathology
  • Male
  • PPAR gamma / agonists
  • PPAR gamma / genetics*
  • PPAR gamma / metabolism
  • Phosphorylation / drug effects
  • RNA, Small Interfering / genetics
  • Rats
  • Rats, Inbred OLETF
  • Receptors, G-Protein-Coupled / agonists
  • Receptors, G-Protein-Coupled / antagonists & inhibitors
  • Receptors, G-Protein-Coupled / genetics*
  • Receptors, G-Protein-Coupled / metabolism
  • Rosiglitazone
  • Signal Transduction / drug effects
  • Thiazolidinediones / pharmacology*
  • Trans-Activators / genetics
  • Trans-Activators / metabolism

Substances

  • Cyclic AMP Response Element-Binding Protein
  • Fatty Acids, Nonesterified
  • G-protein-coupled receptor 40, rat
  • Glucose Transporter Type 2
  • Homeodomain Proteins
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Irs2 protein, rat
  • PPAR gamma
  • RNA, Small Interfering
  • Receptors, G-Protein-Coupled
  • Slc2a2 protein, rat
  • Thiazolidinediones
  • Trans-Activators
  • pancreatic and duodenal homeobox 1 protein
  • Rosiglitazone
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium

Grants and funding

This work was supported by funds from the Ministry of Health and Welfare, Republic of Korea (A080513). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.